Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Patients with prostate cancer exhibit changes in the levels of some urinary molecules compared with people with benign prostate diseases and ... Read more
Adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extends the lives ... Read more
High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are associated with increased risk of prostate cancer ... Read more
Most prostate cancer patients who choose to undergo active surveillance instead of treatment are not receiving the appropriate disease monitoring, bringing ... Read more
Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods ... Read more
Long-term treatment with atorvastatin, a cholesterol-lowering medicine, may reduce the proliferation of prostate cancer cells in some patients, a randomized trial suggests. ... Read more
Long-term use of androgen deprivation therapy (ADT) can make prostate cancer lesions difficult or impossible to see on some imaging scans, even in ... Read more
